Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Omega Therapeutics, Inc. Market Cap
Based on ratings from 0 stock analysts, the Omega Therapeutics, Inc. stock price is expected to increase by 877.19% in 12 months. This is calculated by using the average 12-month stock price forecast for Omega Therapeutics, Inc.. The lowest target is $7 and the highest is $15. Please note analyst price targets are not guaranteed and could be missed completely.
Omega Therapeutics, Inc. has a total of 0 Wall St Analyst ratings. There are 0 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a sell consensus rating, the expectation is that Omega Therapeutics, Inc. will perform worse than the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of OMGA.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Robert Burns HC Wainwright & Co. | Buy | $12 | Reiterates | Aug 15, 2024 |
| Keay Nakae Chardan Capital | Buy | $6 | Maintains | Aug 7, 2024 |
| Robert Driscoll Wedbush | Outperform | $12 | Reiterates | Aug 7, 2024 |
| Ryan Deschner Raymond James | Outperform | $12 | Initiates | Jun 18, 2024 |
| Robert Burns HC Wainwright & Co. | Buy | $12 | Reiterates | May 13, 2024 |
| Keay Nakae Chardan Capital | Buy | $7 | Maintains | May 7, 2024 |
| Robert Burns HC Wainwright & Co. | Buy | $12 | Reiterates | Apr 30, 2024 |
| Edward Tenthoff Piper Sandler | Overweight | $9 | Reiterates | Apr 3, 2024 |
| Keay Nakae Chardan Capital | Buy | $7 | Maintains | Apr 1, 2024 |
| Robert Driscoll Wedbush | Outperform | $12 | Reiterates | Jan 4, 2024 |
| Robert Burns HC Wainwright & Co. | Buy | $12 | Maintains | Nov 13, 2023 |
| Robert Driscoll Wedbush | Outperform | $12 | Maintains | Nov 10, 2023 |
| Robert Burns HC Wainwright & Co. | Buy | $11 | Reiterates | Sep 1, 2023 |
Chardan Capital | Buy | Reiterates | Aug 4, 2023 | |
| Robert Burns HC Wainwright & Co. | Buy | $11 | Reiterates | Jun 6, 2023 |
| Keay Nakae Chardan Capital | Buy | $12 | Reiterates | May 8, 2023 |
| Robert Burns HC Wainwright & Co. | Buy | $11 | Reiterates | Mar 31, 2023 |
| Robert Burns HC Wainwright & Co. | Buy | $11 | Reiterates | Mar 24, 2023 |
| Catherine Novack JonesTrading | Buy | $11 | Initiates | Mar 10, 2023 |
| Edward Tenthoff Piper Sandler | Overweight | $10 | Maintains | Mar 3, 2023 |
When did it IPO
2021
Staff Count
93
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Mahesh Karande
Market Cap
$62.9M
In 2023, OMGA generated $3.1M in revenue, which was a increase of 49.25% from the previous year. This can be seen as a signal that OMGA's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 17 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Omega Therapeutics published preclinical data in Nature Communications on OTX-2002, which targets the MYC gene in liver cancer, indicating potential for precision epigenomic therapies.
Why It Matters - The publication of promising preclinical data for OTX-2002 enhances Omega Therapeutics' credibility and potential for future commercialization, impacting its stock value and investor interest in biotech innovations.
Wed, 14 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Omega Therapeutics has appointed Jennifer Nelson, Ph.D., as Senior VP of Research, enhancing its leadership with her 20+ years in RNA and DNA therapies.
Why It Matters - The appointment of Dr. Jennifer Nelson enhances Omega Therapeutics' leadership in RNA therapies, potentially driving innovation and growth, which can positively impact investor sentiment and stock performance.
Tue, 06 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Omega Therapeutics, Inc. (Nasdaq: OMGA) reported its Q2 financial results for 2024, showcasing advancements in its programmable epigenomic mRNA medicines.
Why It Matters - Omega Therapeutics' financial results and advancements in programmable mRNA medicines signal growth potential, impacting stock performance and investor sentiment in the biotech sector.
Tue, 06 Aug 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Omega Therapeutics, Inc. (OMGA) reported a quarterly loss of $0.30 per share, beating the Zacks Consensus Estimate of $0.36, and improving from a loss of $0.54 per share a year earlier.
Why It Matters - Omega Therapeutics' smaller-than-expected loss signals improved financial performance, potentially boosting investor confidence and impacting stock price positively.
Mon, 24 Jun 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - A former Merck executive with extensive experience in corporate finance, business development, and corporate licensing has joined a new organization.
Why It Matters - The hiring of a former Merck veteran indicates potential for strategic growth and improved financial management, enhancing investor confidence in the company's future performance.
Wed, 29 May 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Omega Therapeutics appointed Kaan Certel, Ph.D., as Chief Business Officer to oversee global business development and strategic partnerships, enhancing its position in programmable epigenomic mRNA medicines.
Why It Matters - Kaan Certel's appointment as Chief Business Officer signals Omega Therapeutics' focus on strategic partnerships, potentially enhancing growth and innovation, which can positively impact stock performance.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
